GlassScriptPhysician profile
Balbir Singh
NPI 1114013927
$4,739.88
in general payments reported to CMS, 2019-2025
38 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $50.58 · 2021: $364 · 2022: $658 · 2023: $990 · 2024: $1,076 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262 · Education: $48.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.76 |
| Education | $48.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $862.22 | 2019-2025 | Krystexxa, Repatha, Tavneos |
| Astrazeneca Pharmaceuticals LP | $564.85 | 2019-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $352.80 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.19 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $260.14 | 2023-2025 | |
| Horizon Therapeutics Plc | $195.95 | 2022-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $191.38 | 2021-2024 | |
| Vifor Pharma, INC. | $174.62 | 2019-2023 | Veltassa, Korsuva |
| Ardelyx, INC. | $164.12 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $161.65 | 2023-2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $149.58 | 2022-2023 | Verquvo |
| Lilly USA, LLC | $147.21 | 2019-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $144.91 | 2021-2024 | Acthar |
| Akebia Therapeutics INC | $143.73 | 2019-2025 | Vafseo, Auryxia |
| Neurocrine Biosciences, INC. | $125.50 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balbir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.